Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 328
- Registration Number
- NCT00505622
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Hospital Purpan, Toulouse, Toulouse Cedex, France
A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2009-03-24
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 40
- Registration Number
- NCT00459823
- Locations
- 🇪🇸
Medical Oncology Service. Vall d'Hebron University Hospital, Barcelona, Spain
🇳🇱Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, Netherlands
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 723
- Registration Number
- NCT00360308
- Locations
- 🇫🇷
Pavillon Riser- Hopital Purpan, Toulouse Cedex, France
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
- Conditions
- Parkinson's Disease
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 702
- Registration Number
- NCT00286897
- Locations
- 🇧🇪
C.H.U.de Charleroi, Charleroi, Belgium
🇧🇪Hopital St-Pierre, Ottignies, Belgium
🇨🇿Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czech Republic
An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects
- Conditions
- Spasmodic Torticollis
- Interventions
- Drug: E2014 (Botulinum toxin type B)Drug: E2014 (Botulinum toxin type B) Placebo
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 48
- Registration Number
- NCT00280384
Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
- Conditions
- Epilepsy
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 1000
- Registration Number
- NCT00215592
- Locations
- 🇦🇹
Universitatsklinikum fur Neurologie, Innsbruck, Austria
🇩🇰Danish Epilepsy Center, Dianalund, Denmark
🇩🇰The Epilepsy Clinic, Glostrup, Denmark
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 62
- Registration Number
- NCT00165880
- Locations
- 🇷🇺
Leningrad Regional Oncology Center, Kuzmolovo, Russian Federation
🇪🇸Hospital Unicersaitario de La Princesa, Madrid, Spain
🇩🇪Stadt Kliniken Frankfurt-Hochst, Frankfurt, Germany
Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer (CRC)
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 46
- Registration Number
- NCT00165854
- Locations
- 🇫🇷
Institut Curie, Paris, France
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇩🇪Universitätsklinikum der GHS-Essen, Essen, Germany
A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease
- Conditions
- Lesion
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2010-01-29
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165620
A Comparative Study of KES524 in Patients With Obesity Disease
- Conditions
- Obesity
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2010-01-29
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165685